ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1564

Efficacy Of Influenza Vaccination Is Strongly Decreased In Systemic Lupus Erythematosus: A Meta-Analysis Of Literature Data

Laurent Arnaud1, Alexis Mathian2, Hervé Devilliers3, Du Boutin-LE Thi Huong4, Ahlem Chaib4, Fleur Cohen-Aubart4, Julien Haroche1, Miguel Hié4, Makoto Miyara4 and Zahir Amoura4, 1Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 2Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, 3Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, 4Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: meta-analysis, systemic lupus erythematosus (SLE) and vaccines

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Several studies suggest that the efficacy of influenza vaccination may be decreased in systemic lupus erythematosus (SLE). We performed a meta-analysis to assess systematically the immunogenicity of influenza vaccination in SLE, comparatively to healthy subjects.

Methods:

All studies published until February 2013, comparing the immunogenicity of influenza vaccination in SLE comparatively to healthy subjects were identified from the MEDLINE, Cochrane and EMBASE databases and included in our meta-analysis. The immunogenicity was evaluated using the proportion of subjects with influenza antibody titers ≥1:40 (seroprotection rate) and the proportion of subjects with either a prevaccination hemagglutination-inhibiting titer <1:10 and a postvaccination titer ≥1:40 or a prevaccination titer ≥1:10 and an increase in the titer by a factor of 4 or more (seroconversion rate). Pooled effect estimates were obtained using a random-effects model.

Results:

Of 146 citations retrieved, 16 primary studies including 1010 SLE patients and 578 healthy controls met inclusion criteria. Pooled analysis revealed significantly decreased immunogenicity of H1N1 influenza vaccine in SLE patients compared to healthy controls for both seroprotection rates (Odd Ratio, OR:  0.34 [95% confidence interval, 95%CI: 0.21 – 0.55]) and seroconversion rates (OR: 0.34 [95%CI: 0.21 – 0.56]) with significant statistical heterogeneity for seroconversion (T² = 0.37; p = 0.01; I² = 0.54). Our meta-analysis also reveals significantly decreased seroprotection rates with H3N2 (OR: 0.34 [95%CI: 0.18 – 0.66]) and B (OR: 0.40 [95%CI: 0.22 – 0.73]) influenza vaccines and non-significantly decreased seroconversion rates for H3N2 (OR: 0.55 [95%CI: 0.21 – 1.45]) and B (OR: 0.44 [95%CI: 0.19 – 1.01]) influenza vaccines. Subgroup analyses considering only SLE patients without corticosteroids and immunosuppressors (n=209) revealed non significantly decreased seroprotection rate (OR: 0.60 [95%CI: 0.35 – 1.01]) and decreased seroconversion rate (OR: 0.64 [95%CI: 0.42 – 0.98]) compared with healthy controls (n=226).

Conclusion:

Our meta-analysis demonstrates significantly decreased immunogenicity of influenza vaccines in SLE compared to healthy patients. Subgroup analysis suggests that decreased immunogenicity may be independent of immunosuppressive treatments. Specific vaccination schemes, -such as the use of a second injection or the use of adjuvanted vaccines-, should be evaluated in SLE patients.


Disclosure:

L. Arnaud,
None;

A. Mathian,
None;

H. Devilliers,
None;

D. Boutin-LE Thi Huong,
None;

A. Chaib,
None;

F. Cohen-Aubart,
None;

J. Haroche,
None;

M. Hié,
None;

M. Miyara,
None;

Z. Amoura,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-influenza-vaccination-is-strongly-decreased-in-systemic-lupus-erythematosus-a-meta-analysis-of-literature-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology